Ingredient or product comparison
GHK-Cu Cosmetic Legal 2026 Status: Comparison Table
United States (FDA) Legal as cosmetic ingredient Facility registration under MoCRA; adverse event reporting No explicit limit; market practice 0.001–1% No drug claims (treat, prevent, cure disease); no structure-function claims Claim-triggered; warning letters
This source-based comparison does not add ratings or recommend a winner.
- United States (FDA)
- Legal as cosmetic ingredient
- Facility registration under MoCRA; adverse event reporting
- No explicit limit; market practice 0.001–1%
- No drug claims (treat, prevent, cure disease); no structure-function claims
- Claim-triggered; warning letters for drug-classified products
- European Union
- Legal; requires safety assessment
- Pre-market safety assessment by qualified assessor; Cosmetic Product Safety Report (CPSR)
- No explicit limit; safety assessor determines safe concentration (typically 0.01–0.1%)
- No therapeutic claims; must not imply medical benefit
- Proactive market surveillance; national authority inspections
- United Kingdom
- Legal; follows EU-derived framework
- Safety assessment under UK Cosmetics Regulation; notification to OPSS
- Same as EU; safety assessor determines limit
- Same as EU; therapeutic claims trigger reclassification
- Aligned with EU enforcement; OPSS complaint-driven
- Canada
- Legal; not on Hotlist
- Cosmetic Notification Form (CNF) submission to Health Canada
- No explicit limit; manufacturer responsibility for safety
- Therapeutic claims trigger Natural Health Product (NHP) or drug classification
- Moderate; post-market surveillance and complaint-driven
- Australia (TGA)
- Legal; requires listing on ARTG if making claims
- Listing on Australian Register of Therapeutic Goods (ARTG) if therapeutic claims made
- No explicit cosmetic limit; TGA evaluates case-by-case
- Therapeutic claims require ARTG listing; cosmetic claims exempt
- Moderate; border enforcement and post-market review
- The bottom line: GHK-Cu cosmetic remains legal across all major regulatory markets in 2026, but compliance burden has increased. The shift from voluntary to mandatory registration, combined with heightened scrutiny on peptide efficacy claims, means brands must now document both formulation safety and claim substantiation to avoid reclassification.